As filed with the Securities and Exchange Commission on March 19, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORMS-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SPERO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 46-4590683 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts | 02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
SPERO THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN, AS AMENDED
(Full title of the plan)
Ankit Mahadevia, M.D., Chief Executive Officer and President
Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14th Floor
Cambridge, Massachusetts 02139
(Name and address of agent of service)
(857)242-1600
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☒ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Securities to be Registered | Amount to be Registered (1) | Proposed Maximum Offering Price Per Share (2) | Proposed Maximum Aggregate Offering Price (2) | Amount of Registration Fee | ||||
Common Stock, par value $0.001 per share | 607,324 shares | $5.72 | $3,473,893.28 | $450.91 | ||||
| ||||||||
|
(1) | The number of shares of common stock, par value $0.001 per share (“Common Stock”), of Spero Therapeutics, Inc. (the “Registrant”) stated above consists of additional shares of common stock available for issuance under the Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (the “2017 Plan”), by operation of the 2017 Plan’s “evergreen” provision. The maximum number of shares which may be sold upon the exercise of such options or issuance of stock-based awards granted under the 2017 Plan are subject to adjustment in accordance with certain anti-dilution and other provisions of the 2017 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions. |
(2) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the 2017 Plan are based on the average of the high and the low price of Registrant’s Common Stock as reported on The Nasdaq Global Select Market as of a date (March 16, 2020) within five business days prior to filing this Registration Statement. |
EXPLANATORY NOTE
This registration statement registers an aggregate of 607,324 additional shares of the Registrant’s common stock reserved under the 2017 Plan, representing an increase of 607,324 shares reserved under the 2017 Plan effective January 1, 2020 by operation of the 2017 Plan’s “evergreen” provision. This registration statement registers additional securities of the same class as other securities for which a registration statement filed on FormS-8 (File No.333-222060) relating to an employee benefit plan is effective. The information contained in the Registrant’s registration statement onFormS-8 filed with the Securities and Exchange Commission on December 14, 2017 (FileNo. 333-222060) is hereby incorporated by reference pursuant to General Instruction E of FormS-8.
2
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
3
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on FormS-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on March 19, 2020.
SPERO THERAPEUTICS, INC. | ||
By: | /s/ Ankit Mahadevia, M.D. | |
Ankit Mahadevia, M.D. | ||
Chief Executive Officer and President |
Each person whose signature appears below constitutes and appoints Ankit Mahadevia, M.D. and Stephen J. DiPalma, and each of them singly, his true and lawfulattorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on FormS-8 of Spero Therapeutics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to theattorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that theattorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Ankit Mahadevia, M.D. Ankit Mahadevia, M.D. | Chief Executive Officer and President and Director (Principal Executive Officer) | March 19, 2020 | ||
/s/ Stephen J. DiPalma Stephen J. DiPalma | Interim Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer) | March 19, 2020 | ||
/s/ Milind Deshpande, Ph.D. Milind Deshpande, Ph.D. | Director | March 19, 2020 | ||
/s/ Jean-François Formela, M.D. Jean-François Formela, M.D. | Director | March 19, 2020 | ||
/s/ John C. Pottage, M.D. John C. Pottage, M.D. | Director | March 19, 2020 | ||
/s/ Cynthia Smith Cynthia Smith | Director | March 19, 2020 | ||
/s/ Frank E. Thomas Frank E. Thomas | Director | March 19, 2020 | ||
/s/ Patrick Vink, M.D. Patrick Vink, M.D. | Director | March 19, 2020 |
4